BiomX (PHGE) EBIT : $-34.42 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BiomX EBIT?

BiomX's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-16.47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-34.42 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BiomX's annualized ROC % for the quarter that ended in Mar. 2024 was -109.92%. BiomX's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -504.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BiomX's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 825.12%.

BiomX EBIT Historical Data

The historical data trend for BiomX's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiomX EBIT Chart

BiomX Annual Data

Trend

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-0.41

-30.09

-35.46

-26.18

-23.74

BiomX Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-5.79	-5.66	-7.32	-4.97	-16.47

Competitive Comparison of BiomX's EBIT

For the Biotechnology subindustry, BiomX's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BiomX's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BiomX's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BiomX's EV-to-EBIT falls into.

BiomX EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.42 Mil.

BiomX (AMEX:PHGE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BiomX's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-27.14 * ( 1 - -0.03% )	/	( (13.876	+	35.518)	/ 2 )
=	-27.148142	/	24.697
=	-109.92 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	25.029	-	4.697	-	( 14.907	-	max(0, 11.176	-	17.632	+	14.907	))
=	13.876

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	81.606	-	9.694	-	( 43.007	-	max(0, 10.707	-	47.101	+	43.007	))
=	35.518

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

BiomX's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-65.888	/	( ( (7.397 + max(-2.574, 0))	+	(18.717 + max(-7.869, 0)) )	/	2 )
=	-65.888	/	( ( 7.397	+	18.717 )	/	2 )
=	-65.888	/	13.057
=	-504.62 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.151)	-	(4.697	+	0.028	+	0)
=	-2.574

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.853)	-	(9.694	+	0.028	+	0)
=	-7.869

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BiomX's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-34.424	/	-4.172
	=	825.12 %

BiomX EBIT Related Terms

Thank you for viewing the detailed overview of BiomX's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BiomX (PHGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiomX Inc (AMEX:PHGE) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

22 Einstein Street, Floor 5, Ness Ziona, ISR, 7414003

Website

https://www.biomx.com

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis.

Executives

Assaf Oron	officer: Chief Business Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Eddie Williams	director	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Michael E. Dambach	director	22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003
Jason M. Marks	director	C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Carl L Gordon	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Israel Biofund Gp Limited Partnership	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Chidozie Ugwumba	10 percent owner	158 FILMORE STREET, DENVER CO 80206
Thomas Layton Walton	10 percent owner	P.O. BOX 1860, BENTONVILLE AR 72712
Paul J Sekhri	director	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Lynne Marie Sullivan	director	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Marina Wolfson	officer: Principal Financial Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Jonathan Eitan Solomon	director, officer: Chief Executive Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Alan Charles Moses	director	C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Russell Greig	director	C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Gbolahan Amusa	director	17 STATE STREET 21 FLOOR, NEW YORK NY 10004